Introduction
Potent pro-inflammatory cytokines, such as interleukin 1 (IL-1) or tumor necrosis factor (TNF)a have been found to increase group II phospholipase A2 (PLA2) synthesis and secretion by mesangial cells. In all cases 85-90% of the enzyme is secreted from the cells and a parallel increase in prostaglandin (PG)E2 synthesis is observed. We report here that co-incubation with a monoclonal antibody that specifically binds and neutralizes rat group II PLA2 attenuates IL-1,B and TNFastimulated PGE2 production by 45% and 52%, respectively.
CGP43182, a specific inhibitor of group II PLA2, potently blocks mesangial cell group II PLA2 in vitro with a half-maximal inhibitory concentration (IC50) of 1.5 gM, while only slightly affecting mesangial cell high molecular weight PLA2.
CGP 43182 markedly attenuates IL-1ft-and TNFa-stimulated PGE2 synthesis in intact mesangial cells with IC5o's of 1.3 and 1.0 tM, respectively.
PLA2 secreted from cytokine-stimulated mesangial cells was purified to homogeneity. Addition of the purified enzyme to unstimulated mesangial cells causes a marked release of arachidonic acid and a subsequent increased synthesis of PGE2. Moreover, addition of purified PLA2 to a cloned rat glomerular epithelial cell line and cultured bovine glomerular endothelial cells augmented both arachidonic acid release and PGE2 synthesis, with the endothelial cells being especially sensitive. Phospholipase A2 (PLA2)i comprises a group of lipolytic enzymes that specifically release fatty acids, often arachidonic acid, from the sn-2 position of membrane phospholipids for production of important lipid mediators such as eicosanoids and platelet activating factor ( 1, 2) . It has become evident that PLA2s are a heterogenous family of enzymes that can be classified into two classes, based on their molecular weight. A class of low molecular weight PLA2s ( 14 kD) referred to as secretory PLA2s or sPLA2s and the more recently discovered higher molecular mass enzymes (60-1 10 kD), also referred to as cytosolic PLA2s or cPLA2s. Members of both classes from human and rat sources have recently been cloned (3) (4) (5) (6) (7) (8) . The sPLA2s are further divided into two groups, based on their aminoacid sequence (9) . Mammalian group I PLA2 comprises the pancreatic type ofPLA2 and is characterized by the presence ofCysl 1. Several nonpancreatic tissues contain group II PLA2, which is characterized by the lack of Cysl 1. Mammalian group II PLA2 is found in soluble form at inflammatory sites such as peritoneal exudates (1O, 11) or rheumatoid arthritis (3, 4, 12) , is synthesized and secreted from many cell types, and is believed to play a role in the initiation and propagation ofinflammatory processes ( 13, 14) . In line with this hypothesis, the PLA2 purified from human synovial fluid is proinflammatory and vasoactive, and mediates hyperaemia and a marked inflammatory reaction when injected intracutaneously into rabbits ( 15) or intraarticularly into rats ( 16). Furthermore, injection ofpurified rat platelet PLA2 exacerbated the paw edema in rats with adjuvant arthritis ( 17) .
Moreover, two potent proinflammatory cytokines, IL-1 and TNFa, stimulate PLA2 activity and PG production in several cell systems. IL-1 and TNFa activate membrane-bound PLA2, but also induce the synthesis and secretion of sPLA2 in rabbit and rat chondrocytes ( 18, 19) , human synovial cells (20) , rat mesangial cells (21, 22) , and MDCK cells (23) . The cytokine effect is blocked by actinomycin D and cycloheximide, thus demonstrating a requirement for both transcription and de novo protein synthesis. This is confirmed by the observation that IL-1 and TNFa increase the level of mRNA for group II PLA2 in rabbit articular chondrocytes (24, 25) , rat vascular smooth muscle cells (26) , rat astrocytes (27) , rat mesangial cells (28, 29) , and human hepatoma cells (30) .
Recently, a new family of high molecular weight PLA2s (cPLA2s) has been purified from a variety of cells and tissues, including rat mesangial cells (31, 32) , rat kidney (33), human monoblast cell line U937 (7, 8, 34, 35) , mouse macrophage cell line RAW 264.7 (36) , and platelets (37) (38) (39) Cell culture and incubation. Renal glomeruli from male SpragueDawley rats or from female Wistar rats (80-100 g body wt) were isolated under sterile conditions by a sieving technique, and glomerular cells were cultured as described previously (28, 42) . In a second step, single cells were cloned by limited dilution in 96-microwell plates to obtain pure cultures of epithelial cells and mesangial cells (28, 43 tissue were minced, passed through a sterile 240 Jim stainless steel sieve, and suspended in HBSS. This suspension was then poured through a 180 jim stainless sieve followed by a 100 gm mesh. The glomeruli retained by the 100 jim sieve were washed three times in HBSS and were then incubated for 10 to 15 min at 370C in HBSS containing 1 mg/ml of collagenase (type V; Sigma Chemical Co.). After digestion, glomerular remnants were sedimented at 500 g for 5 min. The supernatant was centrifuged at 1,000 g for 5 min, and the pellet was suspended in RPMI 1640 medium containing 20% FCS, penicillin ( 100 U/ml), streptomycin ( 100 jug/ml), 50 tig/ml heparin sodium, and 5 ng/ml of acidic fibroblast growth factor. Cells were plated on 0.2% gelatin-coated 100 mm-diameter tissue culture plates. Primary cultures ofendothelial cell clones were isolated with cloning cylinders, detached with trypsin-EDTA, and passaged at cloning density onto gelatin-coated 35-mmdiameter plates. Individual clones of endothelial cells were characterized by positive staining for Factor VIII-related antigen and uniform uptake of fluorescent acetylated low-density lipoproteins (47). Negative staining for smooth muscle actin and cytokeratin excluded mesangial cell and epithelial cell contaminations. Cells were utilized at passages 5-7.
Phospholipase A2 assays. sPLA2 activity was determined using [1- 14C] oleate-labeled Escherichia coli as substrate as described (48). The substrate was prepared by growing E. coli in the presence of [1-'4C]-oleate, followed by autoclaving to inactivate endogenous phospholipases. More than 95% of the label incorporated by E. coli was in phospholipid and, as demonstrated by snake venom hydrolysis (Crotalus adamanteus), more than 95% of the [1-'4C] oleate was in the sn-2 position of the phospholipids (48). Assay mixtures (1.0 ml) contained 100 mM Tris/HCl buffer, pH 7.0, 1.0 mM CaCl2, 2.5 X 108 [1-'4C]oleate-labeled E. coli (5 nmol phospholipid, 5-8,000 cpm), and the enzyme to be tested at a dilution producing -5% substrate hydrolysis. CGP 43182 was added when indicated and reaction mixtures were incubated for 1 h at 37°C in a shaking water bath. The reaction was stopped by the addition of 5 ml propan-2-ol/n-heptane/ 1M H2S04 (40:10:1, by vol) followed by 2 ml heptane and 3 ml water. After vigorous shaking and phase separation, an aliquot (2.5 ml) of the upper phase was passed over a column of silicic acid (3.5 X 0.5 cm). Free [1-14C oleic acid was quantitatively eluted with 1 ml ethyl acetate. Radioactivity was determined in a scintillation counter. PLA2 activity is expressed as [1-'4C] oleate radioactivity released by 100 jil of cell culture supernatant. cPLA2 activity was measured in mesangial cell cytosolic fractions in the presence or absence ofCGP 43 182 as previously described (40). 1 -Stearoyl-2-[ 1-'4C ]-arachidonoylglycerophosphocholine was used as substrate. Mesangial cell cPLA2 activity was determined by incubating sonicated substrate vesicles (2 jiM 1 -stearoyl-2-[1-14C] arachidonoyl-sn-glycero-3-phosphocholine [5 nCi], 1 jM sn-1,2-dioleoylglycerol) with 50 mM Hepes, pH 7.4, 1 mg/ml fatty acid-free BSA, 2 mM mercaptoethanol, 1 mM CaCl2, 150 mM NaCl, and test enzyme (diluted in lysis buffer; substrate hydrolysis up to 6%). Stock solution of CGP 43182 was prepared in DMSO and kept at -20°C. Working dilutions (concentration 10 times the assay concentration) were prepared in DMSO/water ( 1:10, by vol) immediately before use and added to the assay mixture in a volume of 1 / 10 the assay volume. The free calcium concentration was IC50 values were determined graphically.
Monoclonal antibodies. Monoclonal antibodies against rat liver mitochondrial phospholipase A2 were prepared as described before (49) . Large amounts of these antibodies were obtained by intraperitoneal injection of hybridomas into Pristane-primed mice, and ascites fluids were harvested after appropriate periods. Monoclonal antibodies were purified on protein A-Sepharose CL-4B (Pharmacia LKB, Uppsala, Sweden) as described by the supplier of this affinity material. Column fractions were tested for antibodies by the double immunodiffusion technique of Ouchterlony as described (50) using goat antimouse IgG. Purified monoclonal antibodies were digested with pepsin to isolate F(ab')2 fragments as described (51 ) . The F(ab')2 fragments were purified by chromatography on HiTrap Protein A pre-packed columns (Pharmacia, Dubendorf, Switzerland) according to the instructions ofthe supplier. Antibody preparations were dialyzed against DME containing 0.1 mg/ ml of fatty acid-free BSA before being added to cell cultures.
Purification of secreted phospholipase A2. Purification of PLA2 from the culture supernatant ofstimulated mesangial cells was done in a single immunoaffinity chromatography stop as previously described (52). An immunoaffinity matrix was prepared by coupling purified monoclonal anti-PLA2antibodies to cyanogen bromide-activated Sepharose 4B (Pharmacia LKB) following the instructions of the suppliers. The culture supernatant of mesangial cells stimulated for 48 h with IL-I#3 (1 nM) plus forskolin (10 MiM) was collected and dialyzed against 20 mM Tris/HCl, pH 7.4, 1 M KCl, 2 mM EDTA, and 20% (vol/vol) glycerol (buffer A). The dialysate (100 ml) was applied to the monoclonal antibody-Sepharose column (bed vol 1.5 ml). After washing with buffer A the column was eluted with 0.1 M glycine, pH 2.5, containing 0.5 M KCl. Flow rate was 15 ml/h, and fractions of 4 ml were collected. Protein was measured by A280nm and PLA2 activity was measured in 25 ,l aliquots ofthe fractions. The eluted PLA2 activity peak was supplemented with BSA and was dialyzed against DME containing 0.1 mg/ml of fatty acid-free BSA.
Determination of arachidonic acid release. Confluent cells in 16-mm-diameter wells were labeled for 24 h with [3H ] arachidonic acid ( I MCi/ml; specific radioactivity 240 Ci/ mmol) in DME, containing 0.1 mg/ml of fatty acid-free BSA. Thereafter, the medium was sampled for remaining radioactivity and the cells were (22) and the fact that these antibodies did not recognize rat pancreatic group I PLA2 (49) . Binding experiments using this monoclonal antibody indicated that nearly all (> 93%) of the secreted PLA2 activity was recognized and precipitated by the monoclonal antibodies coupled to Sepharose, irrespective of the stimulator used (22) . Fig. 1 shows antibody titration experiments of the PLA2 secreted by mesangial cells after exposure to IL-1I3 (1 nM). The activity of this supernatant was 0.6 nmol/min/ml and was comparable to the activities found earlier (21, 22) . 50 Ml of this supernatant was incubated for 15 min at 370C with various amounts of ascites fluid, affinity-purified monoclonal antibodies, or F(ab')2 fractions of affinity-purified monoclonal antibodies and then assayed for residual PLA2 activity as shown in Fig. 1 . All three types of antibody preparations gave similar inhibitions of secreted sPLA2 activity. As a next step, we performed co-incubation experiments, exposing mesangial cells for 24 h to IL-1B ( 1 nM) or TNFa (1 nM), in the presence of high amounts of F(ab')2 fragment, sufficient to block 85-90% of the secreted PLA2 activity. Antibody incubation attenuated IL-I(3- (Fig. 2 ) and TNFa- (Fig. 3 ) stimulated PGE2 synthesis by 45% and 52%, respectively. The inhibitory effect of F(ab')2 fractions was concentration-dependent ( Figs. 2 and 3 ). These data suggest that at least 50% of the cytokine-triggered PGE2 synthesis is mediated by the expression and secretion of sPLA2 in mesangial cells. Ascites fluid and affinity-purified monoclonal antibodies could not be used for this type of experiment as they displayed some intrinsic stimulatory effects on sPLA2 secretion by mesangial cells presumably via their Fe-part (data not shown).
A specific sPLA2 inhibitor attenuates cytokine-stimulated PGE2 synthesis. To further substantiate the role of sPLA2 in cytokine-induced PGE2 formation, we made use of a recently described specific inhibitor of sPLA2, i.e., CGP 43182. CGP 43182 was found to potently inhibit isolated group II PLA2 PLA2 activity (% of control) Ml of the cell culture supernatant was incubated with the indicated amount of monoclonal sPLA2 antibody (o) ascites fluid; (A) affinity purified sPLA2 antibody; (0) F(ab')2 fractions of affinity-purified antibody for 15 (Fig. 6 ) and PGE2 synthesis (Fig. 7 ) from all three cell types examined. It is worth noting that the glomerular endothelial cells are especially sensitive to the addition of sPLA2 with a 88% increase in arachidonic acid release and an approximately fivefold increase in PGE2 synthesis. Addition ofsPLA2 did not affect cell viability as assessed by examination ofcell morphology and by a sensitive colorimetric assay, the MTT test (55) .
The calcium ionophore A23 187 (1 gM) increased arachidonic acid release from mesangial cells by 178±7% (mean±SEM, n = 4) as compared to 69±3% observed after sPLA2 addition as shown in Fig. 8 , well in accordance with previously published data (53 secretion of sPLA2 from mesangial cells in response to IL-1a, IL-1(3, and TNFa. The release of sPLA2 was paralleled by a drastic increase in PGE2 synthesis (21) . Furthermore, IL-13 and TNFa exerted a priming effect on PGE2 production with an amplified response to subsequent angiotensin II and calcium ionophore stimulation (53) . The long lag phase ofseveral hours before the onset of sPLA2 secretion and the inhibition by actinomycin D and cycloheximide indicated that RNA and protein synthesis are involved in these processes. We also demonstrated by immunoblotting and partial sequence analysis of purified sPLA2 that cytokines induce a group II PLA2 in mesan- (31) (32) (33) . Actually, mesangial cells are one of the first cell types that were shown to possess a hormonally regulated high molecular weight PLA2 (31 ) . A role for protein kinase C in the regulation of mesangial cell cPLA2 has been proposed several years before. Phorbol esters that specifically activate protein kinase C stimulate arachidonic acid release and prostaglandin synthesis in mesangial cells (57, 58) and inhibitors of protein kinase C were shown to block this response (59) . Bonventre and colleagues (31, 32) were the first to demonstrate that the peptide hormone vasopressin, which triggers phosphoinositide turnover in mesangial cells (42) , phorbol 12-myristate 13-acetate, and epidermal growth factor stimulated cPLA2 activity in mesangial cells. Whereas activation ofcPLA2 by vasopressin and phorbol esters depends on the presence of protein kinase C and is completely abolished after down-regulation of protein kinase C, the epidermal growth factor-induced cPLA2 activation is not mediated via protein kinase C (32) . Recently, Huwiler et al. (60) have proposed that the e-isoenzyme ofprotein kinase C triggers cPLA2 activation in mesangial cells.
The constitutive expression ofcPLA2 in unstimulated cells, its exclusive intracellular localization, its high sensitivity to calcium, and its regulation by protein kinase C make this enzyme an obvious candidate for the physiological regulation of eicosanoid synthesis in mesangial cells. On the other hand, chronic exposure to proinflammatory cytokines induces the expression of a sPLA2 that is not present in control cells, is mainly secreted, is less sensitive to calcium, and is regulated on a transcriptional level. It is tempting to designate the latter enzyme an inflammatory PLA2 that may be responsible for the excessive formation of prostaglandins observed in cells chronically exposed to cytokines, such as IL-1 or TNFa. However, this concept has to be modified since we and others (40, 41, 61, 62) recently demonstrated that chronic treatment with IL-1fI, TNFa, TGFfB2 enhanced cPLA2 activity in mesangial cells, rheumatoid synovial fibroblasts, lung fibroblasts, and the epithelial carcinoma cell line HEp-2. The IL-I -induced increase in cPLA2 activity is due to increased levels ofcPLA2, mRNA, and protein, as well as to posttranslational modifications, i.e., phosphorylation of cPLA2 by a yet unidentified kinase (62) . Thus, IL-1 induces both synthesis and secretion of sPLA2 and enhanced cPLA2 activity in mesangial cells, and the contribution of both enzymes to arachidonic acid release and subsequent PGE2 synthesis was not clear.
The contribution of sPLA2 to PGE2 synthesis in mesangial cells is supported by the suppression ofIL-I ,-stimulated sPLA2 and PGE2 synthesis by glucocorticoids (56, 63) and by TGF02 when the cells are pretreated by TGFf2 prior to stimulation (52). However, dexamethasone has been shown to inhibit TNFa-triggered increase in cPLA2 activity in the epithelial carcinoma cell line HEp-2 cells (41 ) and also inhibits cPLA2 activity in mesangial cells (Schalkwijk, C., unpublished observations). The fact that sPLA2 is predominantly secreted from the cells into the extracellular space, an environment that provides millimolar concentrations of calcium, and these are quantities sufficient to fully activate sPLA2, strongly suggests that sPLA2 contributes to cytokine-induced PGE2 production. The data provided in this report are in line with this view and indicate a marked contribution of sPLA2 to IL-1f-and TNFa-stimulated arachidonic acid release, and to PGE2 synthesis in mesangial cells. From our antibody neutralization experiments we conclude that at least 50% ofthe cytokine-induced PGE2 synthesis is due to extracellular sPLA2 activity. Moreover, the complete inactivation of extracellular sPLA2 and the small portion of sPLA2 remaining in the cells by the specific inhibitor CGP 43182 causes an -70% inhibition of PGE2 synthesis. Thus, some 50-70% ofIL-l: or TNFa-evoked eicosanoid synthesis is due to sPLA2 activity, at least in mesangial cells. Classically, eicosanoid synthesis is regulated by the availability of arachidonic acid released by PLA2. However, in certain cell types prostaglandin formation also depends on increased activity of another key enzyme, i.e., cyclooxygenase. In synovial cells and fibroblasts IL-1 was first shown to markedly enhance the expression of cyclooxygenase (64, 65) . Two forms of cyclooxygenase are known to be present in eukaryotic cells: a cyclooxygenase 1 that was first purified from ram seminal vesicles and a cytokine-and mitogen-inducible cyclooxygenase 2 (66) . In mesangial cells IL-1, TNF, serum, and phorbol ester have been demonstrated to induce the expression of cyclooxygenase (67, 68) . In this context it is noteworthy that addition of purified sPLA2 to unstimulated mesangial cells only increased PGE2 production twofold (Fig. 7) , whereas IL-1 triggered a 15-fold stimulation of PGE2 formation in the cells (Fig. 2) . Co-induction of sPLA2 and cyclooxygenase may result in a synergistically increased synthesis of PGE2 in mesangial cells.
It has been demonstrated that arachidonic acid and its metabolites produced by one cell type can be further metabolized by other cell types in the vicinity (69) . This is the first report to demonstrate that sPLA2 secreted by one cell type can also act on adjacent cells to release arachidonic acid, which can be used by the cells to generate eicosanoids. Hence, sPLA2 secreted by mesangial cells may act on glomerular endothelial cells and epithelial cells. In this context it is noteworthy that the glomerular endothelium is in close apposition to the mesangium without any interfering basement membrane. This is a unique feature and distinguishes the mesangial interstitial space from other interstitial regions of the body (70) and is especially intriguing, considering the high sensitivity ofglomerular endothelial cells to mesangial cell sPLA2 (Figs. 6 and 7) .
The participation of sPLA2 in arachidonic acid release has also been reported for other cellular systems. Rat sPLA2 added exogenously to calcium ionophore-activated HL-60 granulocytes augmented their production of PGE2 (71 ). Murakami et al. (72) reported that rat mast cells, sensitized by IgE and exposed to antigen and sPLA2, markedly increase PGD2 production. Both the generation of PGD2 and the release of arachidonic acid were abolished by inhibitors ofsPLA2. Mouse fibroblasts stably transfected with a human sPLA2-cDNA and overexpressing sPLA2 displayed an enhanced stimulated arachidonic acid release (73) . Moreover, injection of pure recombinant human sPLA2 into the joint space of healthy rabbits elicited a dramatic increase in PGE2 production and an inflammatory, arthritogenic response (74) . Exogenously applied sPLA2 is thought to liberate fatty acids from phospholipids, which are probably located in the outer leaflet of the plasma membrane.
Whether sPLA2 binds to heparan sulfate proteoglycans on mesangial cell surfaces and thus may act as an ectoenzyme as it has been suggested for mast cells (75) remains to be elucidated.
Despite the fact that the monoclonal antibody used in our studies did not pass the plasma membrane of mesangial cells, it blocked 50% of the IL-1# and TNFa-stimulated PGE2 synthesis (Figs. 2 and 3) , suggesting that secreted sPLA2 is able to hydrolyze plasma membrane phospholipids. Furthermore, the released arachidonic acid can be used by the cells for prostaglandin synthesis. Alternatively, exogenous sPLA2 may activate cellular phospholipases, e.g., cPLA2, which subsequently liberate arachidonic acid for eicosanoid synthesis. In a simple mechanistic model, sPLA2-triggered inflammatory reaction comprises the generation of arachidonic acid and lysophospholipids, which are subsequently metabolized into eicosanoids and platelet activating factor. Moreover, arachidonic acid and lysophospholipids may act themselves as signaling molecules. An especially intriguing possibility is a sPLA2-mediated activation of protein kinase C (76). Cis-unsaturated fatty acids, which are produced from phospholipids by the action ofa nonselective-type of PLA2, such as sPLA2, augment the 1,2-diacylglycerol-induced activation ofprotein kinase C. In addition, lysophospholipids interact with the protein kinase C pathway and potentiate the 1,2-diacyglycerol-dependent activation of the enzyme. This stimulatory effect varied with the protein kinase C isoform examined (76). As protein kinase C is able to activate cPLA2 activity in mesangial cells (31 ) , there may be a cross-communication between sPLA2 and cPLA2 pathways. Further work is required to elucidate the complex network of interaction between sPLA2 and cPLA2-triggered mediator release in mesangial cells to evaluate and establish new therapeutic concepts for the treatment ofglomerular inflammatory reactions.
